KalshiFinancials
FDA decision: bictegravir 75 mg/lenacapavir 50 mg (BIC/LEN) by Gilead Sciences (in 2026)
FDA decision on bictegravir 75 mg/lenacapavir 50 mg (BIC/LEN) in 2026
Ends Aug 27, 2026
Bet NowDisclosure
18+ only. Event contracts carry significant risk and are not suitable for everyone, you can lose the entire amount you commit. Not available in all jurisdictions; restrictions and eligibility requirements apply.
- a full approval or an accelerated approval703.8 VOL.Yes 88%No 12%88¢
Rules Summary
If the FDA's decision on bictegravir 75 mg/lenacapavir 50 mg (BIC/LEN) by Gilead Sciences in 2026 is a full approval or an accelerated approval, the market resolves to Yes.
Timeline and Payout
- Opened
- Jun 17, 2026, 9:00 PM
- Closes
- Aug 27, 2026, 10:15 PM
- Pays out
- 0.5 hours after close
Series KXBICTEGRAVIR · Event KXBICTEGRAVIR-27 · Market KXBICTEGRAVIR-27-Y